EGFR-IN-44
Product Specifications
UNSPSC Description
EGFR-IN-44 (Compound 6a) is a potent, orally active EGFR tyrosine kinase inhibitor with an IC50 of 4.11 nM. EGFR-IN-44 induces cell apoptosis and shows an oral bioavailability value of 33.57%. EGFR-IN-44 can be studied for non-small-cell lung cancers[1].
Target Antigen
Apoptosis; EGFR
Type
Reference compound
Related Pathways
Apoptosis;JAK/STAT Signaling;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/egfr-in-44.html
Solubility
10 mM in DMSO
Smiles
C=CC(NC1=CC(NC2=NC(C3=CSC4=CC=CC=C43)=C(C=N2)Cl)=C(C=C1N(CCN(C)C)C)OC)=O
Molecular Weight
537.08
References & Citations
[1]Baijiao An, et al. Novel third-generation pyrimidines-based EGFR tyrosine kinase inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer. Bioorg Chem. 2022 May;122:105743.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-145844/EGFR-IN-44-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-145844/
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MAV124 1 mg
Recombinant Human anti-SARS-CoV-02/COVID-019 RBD Monoclonal Neutralizing Antibody
Ask
View Details 
MBS1003391-01 0.02 mg (E-Coli)
Recombinant Bordetella petrii ATP synthase epsilon chain (atpC)
Ask
View Details MBS1003391-02 0.1 mg (E-Coli)
Recombinant Bordetella petrii ATP synthase epsilon chain (atpC)
Ask
View Details MBS1003391-03 0.02 mg (Yeast)
Recombinant Bordetella petrii ATP synthase epsilon chain (atpC)
Ask
View Details